[an error occurred while processing this directive] | [an error occurred while processing this directive]
Observation of short-term clinical efficacy and adverse reactions with stereotactic radiotherapy in locally recurrent non-small cell lung cancer
Xu Xiuli1, Hu Zongtao1, Lu Donghui2, Gao Shile1
1Department of Oncology,Cancer Hospital,Chinese Academy of Sciences,Hefei 230031,China; 2Department of Forth Oncology, No.901 Hospital of PLA Support Unit, Hefei 230031,China
AbstractObjective To investigate the short-term clinical efficacy and adverse reactions of stereotactic radiotherapy (SRT) in the treatment of locally recurrent non-small cell lung cancer (NSCLC). Methods Clinical data of 120 cases of recurrent NSCLC after radiotherapy admitted to our hospital from October 2009 to October 2015 were retrospectively analyzed. SRT was adopted for further radiotherapy. The prescription dose was 50% dose curve surrounding the target area. The total dose was 40-50 Gy, with a single dose of 4-5 Gy for 8-12 times. The chest CT was re-examined every 2 months after radiotherapy. The short-term clinical efficacy and adverse reactions were evaluated. The changes of Karnofsky performance score (KPS) and quality of life (QOL) were recorded before and after radiotherapy. Results One patient terminated the radiotherapy due to grade 3 acute radiation-induced pneumonia,25 patients (21.0%) obtained complete remission (CR), 61 cases (51.3%) of partial remission (PR), 19 cases (16.0%) of stable disease (SD), 14 cases (11.8%) of progress disease (PD), 86 cases (72.3%) of objective remission rate (CR+PR), and 105 cases (88.2%) of disease control (CR+PR+SD), respectively. Thirty-one patients experienced radiation-induced pneumonia, 23 cases of radiation-induced myelosuppression and 1 case of acute radiation-induced heart injury. All these adverse reactions were mitigated after symptomatic treatment. The KPS was significantly increased from 68.16±15.22 before SRT to 78.39±11.50 after SRT (P<0.05). The QOL was considerably elevated from 27.58±5.37 prior to SRT to 38.16±8.39 following SRT (P<0.01). Conclusion SRT is an efficacious and safe treatment of locally recurrent NSCLC, which yields controllable and tolerable adverse reactions and enhances the QOL of patients.
Corresponding Authors:
Hu Zongtao, Email:huxuyan@163.com
Cite this article:
Xu Xiuli,Hu Zongtao,Lu Donghui et al. Observation of short-term clinical efficacy and adverse reactions with stereotactic radiotherapy in locally recurrent non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2019, 28(7): 495-498.
Xu Xiuli,Hu Zongtao,Lu Donghui et al. Observation of short-term clinical efficacy and adverse reactions with stereotactic radiotherapy in locally recurrent non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2019, 28(7): 495-498.
[1]Speicher PD,Englum BR,Ganapathi AM. Ourcomes after treatment of 17378 patients with locally advanced T3N0-2 non-small-cell lung cancer[J]. Eur J Cardiothorac Surg,2015,47(4):636-641. DOI:10.1093/ejcts/ezu270. [2]岳顺,张大红,袁颖. 全脑放疗联合靶向治疗与同步放、化疗治疗非小细胞肺癌脑转移的临床疗效[J]. 安徽医药,2017,21(1):123-126. DOI:10.3969/j.issn.1009-6469.2017.01.033. Yue S,Zhang DH,Yuan Y. Clinical effect of whole brain radiotherapy combined with targeted therapy and synchronous radiotherapy and chemotherapy in the treatment of non-small cell lung cancer with brain metastasis[J]. Anhui Med Pharmaceutical J, 2017,21(1):123-126. DOI:10.3969/j.issn.1009-6469.2017.01.033. [3]韩文建,肖龙敏,吴洪. 胸腔镜联合化疗与单纯化疗对晚期非小细胞肺癌患者预后的影响[J]. 实用癌症杂志,2017,32(7):1152-1155. DOI:10.3969/j.issn.1001-5930.2017.07.033. Han WJ,Xiao LM,Wu H. Effects of thoracic surgery combined with chemotherapy and chemothrapy alone on prognosis of advanced non-small cell lung cancer[J]. Practical J Cancer,2017,32(7):1152-1155. DOI:10.3969/j.issn.1001-5930.2017.07.033. [4]朱勇,鲁正学,朱媛,等. 放疗联合吉西他滨及顺铂放化疗对Ⅲ期非小细胞肺癌患者的疗效及QOL评分的影响[J]. 实用癌症杂志,2018,33(10):1662-1664,1668. DOI:10.3969/j.issn.1001-5930.2018.10.028. Zhu Y,Lu ZX,Zhu Y,et al. The Effect of radiotherapy combined with gemcitabine and cisplatin chemotherapy for patients with stage Ⅲ non-small cell lung cancer and QOL score[J]. Practical J Cancer,2018,33(10):1662-1664,1668. DOI:10.3969/j.issn.1001-5930.2018.10.028. [5]郭雷鸣,丁高峰,徐文才,等. 局部晚期非小细胞肺癌患者血清中Ape1/Ref-1、ICAM-1及IL-17A水平与放射性肺炎发生的相关性研究[J]. 中国肺癌杂志,2018,21(5):383-388. DOI:10.3779/j.issn.1009-3419.2018.05.05. Guo LM,Ding GF,Xu WC,et al. Correlations between Ape1/Ref-1, ICAM-1 and IL-17A Levels in serum and radiation pneumonitis for local advanced non-small cell lung cancer patients[J]. Chin J Lung Cancer, 2018,21(5):383-388. DOI:10.3779/j.issn.1009-3419.2018.05.05. [6]Bradley JD,Paulus R,Komaki R,et al. Standard-dose versus highdose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or wilhout cetuximab for patients with stage Ⅲ a or Ⅲ b non-small-cell lung cancer (RTOG0617):a randomised,two-by-two factorial phase 3 Study[J]. J Clin Oncol,2015,16(2):187-199. DOI:10.1016/S1470-2045(14)71207-0. [7]Eroglu C,Orhan O,Unal D,et alConcomitant chemoradiotherapy with docetaxel and cisplatin followed by consolidation chemotherapy in locally advanced umresectable non-small cell lung cancer[J]. Ann Thorac Med,2013,8(2):109-115. DOI:10.4103/1817-1737.109824. [8]彭云武,孔亚梅,朱江,等.30例非小细胞肺癌再程放疗临床观察[J]. 现代肿瘤医学,2010,18(10):2062-2063. DOI:10.3969/j.issn.1672-4992.2010.10.66. Peng YW,Sun YM,Zhu J,et al. Clinical observation of 30 patients with non-small cell lung cancer treated with secondary radiotherapy[J]. Mod Oncol,2010,18(10):2062-2063. DOI:10.3969/j.issn.1672-4992.2010.10.66. [9]董昭,李琦,秦庆亮,等. 立体定向放疗联合化疗治疗放疗后局部复发非小细胞肺癌的疗效[J]. 肿瘤,2009,29(12):1133-1136. DOI:10.3760/cma.j.issn.1007-1245.2017.21.011. Dong Z,Li Q,Qing QL,et al. Stereotactic radiation therapy combining chemotherapy in treatment of locally recurrent non-small cell lung cancer after radiotheroapy[J]. Tumor,2009,29(12):1133-1136. DOI:10.3760/cma.j.issn.1007-1245.2017.21.011. [10]Ali A,Goffin JR,Arnold A,et alSurvival of patients with non-small-cell lung cancer after a diagnosis of brain metastases[J]. Curr Oncol,2013,20(4):E300-E306. DOI:10.3747/co20.1481. [11]马震宇,曹海英,张建宇,等. 体部伽玛刀治疗中晚期非小细胞肺癌96例临床分析[J]. 现代肿瘤医学,2017,25(8):1220-1223. DOI:10.3969/j.issn.1672-4992.2017.08.012. Ma ZY,Cao HY,Zhang JY,et al. Clinical analysis of 96 cases of middle-late stage non-small cell lung cancer treated with body gamma knife[J]. J Mod Oncol,2017,25(8):1220-1223. DOI:10.3969/j.issn.1672-4992.2017.08.012. [12]胡宗涛,陆林,朱捷,等. 伽马刀治疗老年非小细胞肺癌近期疗效观察[J]. 安徽医学,2013,34(7):952-953. DOI:10.3969/j.issn.1000-0399.2013.07. Hu ZT,Lu L,Zhu J,et al. Observation on the short-term efficacy of gamma knife in the treatment of senile non-small cell lung cancer[J]. Anhui Med J,2013,34(7):952-953. DOI:10.3969/j.issn.1000-0399.2013.07.